

5-5-05

IPce

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.97(c))

 Docket No.
 DSI-10402/22

In Re Application: Lawrence W. Cosenza

MAY 04 2005

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/735,203	12/12/2003		25006	1645	2593

Title: SACROMASTIGOPHORIC THERAPEUTIC AGENT DELIVERY SYSTEM

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 07-1180 as described below.

- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

May 4, 2005

(Date)

Erica L. Triner

Signature of Person Mailing Correspondence

Erica L. Triner

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Avery N. Goldstein
 Signature

Dated:

May 2, 2005

Avery N. Goldstein, Reg. 39,204
 Gifford, Krass, Groh, Sprinkle,
 Anderson, & Citkowski, P.C.
 P.O. Box 7021
 Troy, MI 48007-7021
 (248) 647-6000

CC:


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
 DSI-10402/22

In Re Application Of: Lawrence W.Cosenza

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/735,203	12/12/2003		25006	1645	2593

Title: SACROMASTIGOPHORIC THERAPEUTIC AGENT DELIVERY SYSTEM



Address to:
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)	DSI-10402/22	Application Number
Applicant(s)	Lawrence W. Cosenza	10/735,203
Filing Date	December 12, 2003	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
<i>O I P E</i> MAY 04 2005 T & P A C E M A P C E R	Bishop, J.R., Shimamura, M., and Hajduk, S.L. (2001) "Insight into the mechanism of trypanosome lytic factor-1 killing of <i>Trypanosoma brucei brucei</i> ." <i>Molecular & Biochemical Parasitology</i> , 118, 33-40.
	Damian, R.T. (1997). "Parasite immune evasion and exploitation: Reflections and projections." <i>Parasitology</i> , 115, S169-S175.
	Furger, A., Jungi, T.W., Salomone, J.-Y., Weynants, V., and Roditi, I. (2001). "Stable expression of biologically active recombinant bovine interleukin-4 in <i>Trypanosoma brucei</i> ." <i>FEBS Letters</i> , 508, 90-94.
	Lotze, M.T., and Kost, T.A. (2002). "Viruses as gene delivery vectors: Applications to gene function, target validation and assay development." <i>Cancer Gene Therapy</i> , 9(8), 692-699.
	Pearson, T.W., Beecroft, R.P., Welburn, S.C., Ruepp, S., Roditi, I., Hwa, K. Y., Englund, P.T., Wells, C.W., and Murphy, N.E. (2000). "The major cell surface glycoprotein procyclin is a receptor for induction of a novel form of cell death in African trypanosomes in vitro." <i>Molecular and Biochemical Parasitology</i> , 111(2), 333-349.
	Porcel, B.M., Tran, A.-N., TAmmi, M., Nyarady, Z., Rydaker, M., Urmenyi, T.P., Rondinelli, E., Pettersson, U., Anderson, B., and Aslund, L. (2000). "Gene survey of the pathogenic protozoan <i>Trypanosoma cruzi</i> ." <i>Genome Research</i> , 10, 1103-1107.
	Santos, W.G.d., and Buck, G.A. (2000). "Simultaneous stable expression of neomycin phosphotransferase and green fluorescence protein genes in <i>Trypanosoma cruzi</i> ." <i>Journal of Parasitology</i> , 86(6), 1281-1288.
	Shimamura, M., Hager, K.M. and Hajduk, S.L. (2001). "The lysosomal targeting and intracellular metabolism of trypanosomal lytic factor by <i>Trypanosoma brucei brucei</i> ." <i>Molecular and Biochemical Parasitology</i> , 115, 227-237.
	Stoka, V., Turk, B., Schendel, S.L., Kim, T.-H., Cirman, T., Snipas, S.J., Ellerby, L.M., Bredesen, D., Freeze, H., Abrahamson, M., Bromme, D., Krajewski, S., Reed, J.C., Yin, X.-M., Turk, V., and Salvesen, G.S. (2001). "Lysosomal Protease Pathways to Apoptosis." <i>Journal of Biological Chemistry</i> , 276(5), 3149-3157.
	Teixeira, A.R.L., Arganarex, E.R., Jr., L.H.F., Lacava, Z.G.M. and Santana, J.M. (1994). "Possible integration of <i>Trypanosoma cruzi</i> kDNA minicircles into the host cell genome by infection." <i>Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis</i> , 305(2), 197-209.
	Trudeau, C., Yuan, S., Galipeau, J., Benlimame, N., Alaoui-Jamali, M.A., and Batist, G. (2001). "A novel parasite-derived suicide gene for cancer gene therapy with specificity for lung cancer cells." <i>Human Gene Therapy</i> , 12(13), 1673-1680.
	Villalta, F., Smith, C.M., Ruiz-Ruano, A., and Lima, M.F. (2001). "A ligand that <i>Trypanosoma cruzi</i> uses to bind to mammalian cells to initiate infection." <i>FEBS Letters</i> , 505(3), 383-388.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)

DSI-10402/22

Application Number

10/735,203

Applicant(s)

Lawrence W. Cosenza

Filing Date

December 12, 2003

Group Art Unit

1645

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Wen, L.-M., Xu, P., Benegal, G., Carvaho, M.R.C., and Butler, D.R. (2001). "Trypanosoma cruzi: Exogenously regulated gene expression." *Experimental Parasitology*, 97, 196-204.

Wirtz, E., Leal, S., Ochatt, C., and Cross, G.M., (1999). "A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in *Trypanosoma brucei*." *Molecular and Biochemical Parasitology*, 99(1), 89-101.

Vrucht, D., Aitcheson, N., and Rudenko, G. (2003). "Downregulation of *Trypanosoma brucei* VSG expression site promoters on circular bacterial artificial chromosomes." *Molecular and Biochemical Parasitology*, 128, 123-133.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)

DSI-10402/22

Application Number

10/735,203

Applicant(s)

Lawrence W. Cosenza

Filing Date

December 12, 2003

Group Art Unit

1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		6,143,551	11/7/2000	Goebel	435	252.3	
		6,287,556 B1	9/11/2001	Portnoy et al.	424	93.1	

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

	Roy, Gaetan et al. (2000) "Episomal and stable expression of the licoferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models," Molecular and Biochemical Parasitology, 110, 195-206.
	Norris, Karen A. (1998) "Stable Transfection of Trypanosoma cruzi Epimastigotes with the Trypomastigote-Specific Complement Regulatory Protein cDNA Confers Complement Resistance," Infection and Immunity, 2460-2465.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)

DSI-10402/22

Application Number

10/735,203

Applicant(s)

Lawrence D. Cosenza

Filing Date

December 12, 2003

Group Art Unit

1645

*EXAMINER
INITIAL

OTHER DOCUMENTS. (Including Author, Title, Date, Pertinent Pages, Etc.)

Furges, A. et al. (2001) "Stable expression of biologically active recombinant bovine interleukin-4 in *Trypanosoma brucei*." FEBS Letters, 508, 90-94.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.